Abstract: A medicament for prophylaxis or treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes, which comprise as an active ingredient a sulphostin-related compound represented by general formula (I): wherein n is an integer of 0 to 3, or a pharmacologically acceptable salt thereof.

Abstract: A medicament for prophylaxis or treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes, which comprise as an active ingredient a sulphostin-related compound represented by general formula (I): 1

Abstract: Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Abstract: Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Abstract: Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Abstract: Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Abstract: Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Abstract: Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Abstract: The invention provides crystalline deoxyspergualin trihydrochloride, a process for the preparation of the same and a suppository composition containing the same. The compound and composition has antitumor and immunosuppressive activity.

Abstract: Novel spergualin-related compounds represented by the general formula (I): ##STR1## wherein X represents --(CH.sub.2).sub.1-5 -- or a phenylene group which may be substituted; m represents 0, 1 or 2; n represents 1 or 2; and R.sub.1 represents --(CH.sub.2).sub.1-3 --COOH, and pharmacologically acceptable salts thereof, possess an immunopotentiating activity, and are expected to be useful as immunopotentiators applicable to warm blooded animals.

Abstract: The present invention relates to novel spergualin-related compounds represented by the general formula [I]: ##STR1## wherein X is --(CH.sub.2).sub.1.about.5 or ##STR2## Y is a hydrogen atom or a residue obtained by removing a hydroxyl group from the carboxyl group of an amino acid or a peptide; m is 0, 1 or 2 and n is 1 or 2, with the proviso that Y is not a hydrogen atom when n is 2 and m is 0.This compounds are stable and exhibit a high immunosuppressive activity.

Abstract: An agent for relieving radiogenic or drug-induced side effects, characterized by comprising a spergualin derivative of the following formula (I):NH.sub.2 --C(.dbd.NH)--NH--R.sub.1 --R.sub.2 --CONH--R.sub.3 --CONH--(CH.sub.2).sub.4 --NH--(CH.sub.2).sub.3 --NH--Xwherein R.sub.1 represents --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.6 ##STR1## R.sub.2 represents --(CH.sub.2).sub.2 -- or --CH.dbd.CH--, R.sub.3 represents --(CH(OH)--CH(OMe)--, --CH.sub.2 -- or --(CH.sub.2).sub.m --CH(OH)--(CH.sub.2).sub.n -- (m represent an integer of 0,1 or 2 and n represents an integer of 1 or 2)X represents a hydrogen atom or a group formed by removing a hydroxyl group from a carboxyl group of an amino acid,or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: Process for purifying spergualin-related compounds and their synthetic intermediates, by subjecting a solution containing such spergualin-related compounds or intermediates to electrodialysis and/or reverse osmosis.

Abstract: The present invention relates to novel Spergualin-related compounds represented by the general formula [I] ##STR1## (wherein X is ##STR2## R is --H or --CH.sub.2 OH; R.sub.1 is --H, ##STR3## R.sub.2 is a residue obtained by removing, from an amino acid or peptide, the hydroxyl group of the carboxyl group and, when R.sub.1 is a group other than --H, R.sub.2 is same as R.sub.1), or a pharmacologically acceptable salt thereof. Said compounds or salts thereof have an immuno-modulating action.

Abstract: A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certan specified solvents.

Abstract: A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certain specified solvents.

Abstract: The present invention relates to new easily filtrable, non-hygroscopic N-benzyloxycarbonyl-L-threonine amide hemihydrate.

Abstract: A biospecific adsorbent comprising pyroglutamyl-lysyl-leucyl-argininal combined with a water-insoluble support is provided. This biospecific adsorbent is useful as an adsorbent for use in affinity chromatography and can be utilized for the purification of proteases such as urokinase.

Abstract: A process for producing threo-3-amino-2-hydroxybutanoylaminoacetic acids comprises the steps of allowing to react a starting compound represented by the general formula: ##STR1## wherein R.sub.1 represents a naphthyl or a group of the formula: ##STR2## in which R.sub.6 and R.sub.7 represent individually hydrogen, halogen, amino or a protected amino, hydroxy or a protected hydroxy, a lower alkoxy or a lower alkyl and R.sub.2 represents a protected amino, with a starting compound represented by the general formula: ##STR3## wherein R.sub.3 represents hydrogen or an ester residue, to obtain threo-3-protected amino-2-hydroxy-4-oxobutanoic acid or its ester represented by the general formula: ##STR4## wherein R.sub.1, R.sub.2 and R.sub.3 have the same meanings as above, and then reducing the same into threo-3-protected amino-2-hydroxybutanoic acid or its ester represented by the general formula: ##STR5## wherein R.sub.1, R.sub.2 and R.sub.

Abstract: L-Argininal derivatives of the general formula: ##STR1## are disclosed. A method of manufacturing any such derivative is also disclosed. The L-argininal derivative of this invention has a strong inhibitory activity on proteases, such as serine and thiol proteases, and is expected to provide useful medicines, including those which are effective for diseases caused by abnormal elevation of protease activity.